Modulatory actions of XXXX on carcinogen-activating @entity12325 isozymes and the potential for drug interactions in @entity1 hepatocarcinoma cells.

@entity1 @entity137 @entity12325 @entity101 @entity5322 @entity48953 @entity5060 @entity105 @entity4914 @entity25053 @entity5321
CONTEXT: Although @entity1 are exposed to @entity48953 ( @entity25053 ) in their diet, there is no available literature related to drug interaction and the carcinogen-activating potential of @entity25053 in the HepG2 cell line. OBJECTIVE: This study was undertaken to determine the effects of @entity25053 on the @entity4914 , @entity5321 , @entity5060 , and @entity5322 enzymes, which are primarily involved in carcinogen and drug metabolism. MATERIALS AND METHODS: The @entity137 of @entity25053 in HepG2 cells was investigated by measuring the cleavage of WST-1. The protein and mRNA levels of CYPs were determined by western blotting and RT-PCR, respectively. RESULTS: The EC10, EC25, and EC50 values of @entity25053 were calculated to be 1.84, 3.91 and 7.39   mM, respectively. A sublethal dose of 5   mM was used throughout this study. The @entity4914 protein and mRNA levels were increased by 52 and 40% (p   <   0.05), as were the @entity5321 levels by 225 and 424%, respectively (p   <   0.05). However, @entity25053 treatment caused 52 and 60% decreases in the levels of @entity5322 protein and mRNA (p   <   0.05), respectively. In contrast to @entity5322 , the @entity5060 protein and mRNA levels increased by 110 and 130%, respectively. DISCUSSION AND CONCLUSION: Co-administration of @entity25053 with some drugs may lead to undesirable food-drug interactions due to modulatory effects on @entity12325 isozymes involved in drug metabolism. Moreover, exposure to @entity25053 may cause an @entity101 and @entity137 due to the induction of the @entity12325 isozymes involved in chemical @entity105 . Therefore, serious precautions should be taken when using @entity25053 as a supplement.
